The information provided on this website is intended for use by healthcare professionals practicing in the Europe. The dissemination of this information may be subject to different medical and regulatory requirements across Europe.
All the content about BRINEURA®▼ (cerliponase alfa) currently available on CLN2 Meetings platform has been approved and is consistent with the latest and most updated version of EU SmPC.
CLN2 Meetings' content is periodically reviewed by BioMarin and may be subject to changes to assure compliance with European general regulations around on promotion of prescription medicines.
You can always find out the most updated version of Brineura's abbreviated prescribing information (API) under the menu option "API" at the top bar navigation.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.